Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

BACKGROUND: At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized, double-blind, phase III trial, approximately 50% of patients had died. A final analysis of OS was subsequently planned for when 75% o...

Descripción completa

Detalles Bibliográficos
Autores principales: Leo, Angelo Di, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N., Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L., Smirnova, Iya, Lichinitser, Mikhail R., Pendergrass, Kelly, Malorni, Luca, Garnett, Sally, Rukazenkov, Yuri, Martin, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906991/
https://www.ncbi.nlm.nih.gov/pubmed/24317176
http://dx.doi.org/10.1093/jnci/djt337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906991/
https://www.ncbi.nlm.nih.gov/pubmed/24317176
http://dx.doi.org/10.1093/jnci/djt337

Ejemplares similares